STOCK TITAN

TITAN MEDICAL INC ORD Stock Price, News & Analysis

TMDIF OTC

Welcome to our dedicated page for TITAN MEDICAL ORD news (Ticker: TMDIF), a resource for investors and traders seeking the latest updates and insights on TITAN MEDICAL ORD stock.

Titan Medical Inc. (TMDIF) specializes in advanced robotic surgical systems and hybrid imaging technologies designed to transform minimally invasive procedures. This page serves as the definitive source for all company news, providing stakeholders with timely updates on operational milestones, product developments, and strategic initiatives.

Investors and industry professionals will find curated press releases, earnings reports, and merger announcements—including the company’s recent collaboration with Conavi Medical Inc. Content spans regulatory achievements, R&D breakthroughs, and partnerships that underscore Titan Medical’s role in healthcare innovation.

Bookmark this page to stay informed about TMDIF’s progress in robotic surgery advancements and its evolving position within the medical technology sector. Regular updates ensure you never miss critical developments impacting the company’s trajectory.

Rhea-AI Summary

Titan Medical Inc. (TSX: TMD; OTC: TMDIF) has announced a third amendment to its amalgamation agreement with Conavi Medical Inc., originally dated March 17, 2024. The key changes include:

  • Extending the completion deadline to October 10, 2024
  • Reducing the minimum concurrent financing from $15 million to $7.5 million
  • Lowering Titan's required minimum net cash from US$5 million to US$2 million

Additionally, Titan has received approval from the Toronto Stock Exchange to extend its Annual General and Special Meeting of Shareholders to September 30, 2024. This extension allows more time to finalize the proposed merger and avoid potential duplication of costs associated with multiple meetings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Titan Medical has entered into a second amending agreement with Conavi Medical, modifying the timeline for their proposed merger. Key dates have been extended, including the completion of the merger by September 30, 2024, and the commitment for concurrent financing by August 12, 2024. Additionally, Titan is seeking an extension from the Toronto Stock Exchange to hold its Annual General Meeting by September 30, 2024. This extension aims to reduce costs and provide more time to finalize the merger, which requires shareholder approval.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Titan Medical (TSX: TMD; OTC: TMDIF) has amended its amalgamation agreement with Conavi Medical, altering completion timelines for their merger. The new deadlines include:

- August 30, 2024, for the transaction completion.

- June 21, 2024, for financing and Conavi's financial statements.

- June 28, 2024, for mailing AGM information circulars.

- July 26, 2024, for holding AGMs.

Additionally, Conavi has advanced $150,000 to Titan to cover extension-related expenses. Titan has also received an extension from the Toronto Stock Exchange to hold its Annual General Meeting by July 31, 2024, to finalize the merger details.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Titan Medical (TMDIF) updated on its planned merger with Conavi Medical, as per the definitive Amalgamation Agreement dated March 17, 2024.

The merger involves delisting from TSX and listing on TSXV, with required submissions to TSXV currently underway.

A joint management information circular, needing TSXV approval, will be mailed to shareholders before Titan's annual meeting for their approval.

Conavi is also raising a minimum of $15M through subscription receipts convertible into shares before the merger completion.

Further details are available on SEDAR.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Titan Medical Inc. reported financial results for the first quarter of 2024, including recent activities such as entering into an amalgamation agreement with Conavi Medical Inc., settling a contractual dispute, and hosting a Q&A session with shareholders. The company expects to delist its common shares from the Toronto Stock Exchange and list them on the TSX Venture Exchange as part of the transaction. Financial highlights showed a decrease in cash and working capital, a recovery of R&D expenses, and a decrease in general and administrative expenses compared to the previous year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags

FAQ

What is the current stock price of TITAN MEDICAL ORD (TMDIF)?

The current stock price of TITAN MEDICAL ORD (TMDIF) is $0.0327 as of February 7, 2025.

What is the market cap of TITAN MEDICAL ORD (TMDIF)?

The market cap of TITAN MEDICAL ORD (TMDIF) is approximately 4.1M.
TITAN MEDICAL INC ORD

OTC:TMDIF

TMDIF Rankings

TMDIF Stock Data

4.10M
71.8%
1.33%
Medical Devices
Healthcare
Link
Canada
Toronto